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KA WALAN SARAF TERHADAP HAEMODINAMIK 
GINJAL DALAM DIABETES DAN HIPERTENSI : 
PERANAN SUBJENIS ADRENOSEPTOR a 1 
ABSTRAK 
Diabetes dapat mencetuskan perkembangan kerosakan saluran darah yang 
berkaliber kecil dan besar serta saraf periferal dan keadaan ini meningkatkan risiko 
serangan jantung, strok, kebutaan, amputasi dan kegagalan ginjal (Porte dan 
Schwartz, 1996), dan tekanan darah yang tinggi memburukkan lagi kerosakan ini 
(Todd et al., 1993). Adrenoseptor-a.1 diketahui berperanan penting dalam 
vasokonstriksi terhadap rangsangan saraf adrenergik. Akan tetapi, belum ada 
informasi mengenai fungsi daripada subjenis adrenoseptor-a.1 pada rintangan 
pembuluh ginjal dalam diabetes. Kajian ini meneliti peranan subjenis 
adrenoseptor-a.1 dengan cara membandingkan respons vasokonstriksi terhadap 
pelbagai rangsangan adrenergik dengan dan tanpa kehadiran beberapa antagonis 
pada ginjal tikus diabetik dan hipertensi. 
Dalam penyelidikan ini tikus Sprague Dawley (SD), "spontaneously 
hypertensive rats" (SHR) dan "two kidney one clip" (2K1C)-Goldblatt hipertensi 
digunakan. Streptozotocin (STZ) (55 mg/kg, ip) digunakan untuk mengaruh 
diabetes dan tikus-tikus digunakan 7 hari selepas suntikan STZ .. Berat badan 
(BW), pengambilan air (WI} pengeluaran urin (UO), paras glukosa, natrium dan 
kreatinin plasma, ekskresi sodium dan kreatinin selama 24 jam ditentukan. 
Setelah tikus dibiuskan (pentobarbiton, 60 mg/kg), tikus dipersiapkan untuk 
' pengukuran tekanan darah. Gfnjal kiri didedahkan melalui pembedahan bahagian 
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tengah abdomen, dan sebuah prob flowmeter electromagnetik dipasangkan pada 
arteri ginjal untuk mengukur aliran darah. Saraf ginjal dikenalpasti, dan sebuah 
elektrod perangsang bipolar diletakkan padanya. Aliran darah ginjal (RBF) 
terhadap rangsangan langsung saraf ginjal (RNS) pada 1, 2, 4, 6, 8 and 10 Hz, 
15m V dan 2 millisaat selama 20 saat dan pemberian agonis adrenergik 
noradrenalina (25, 50, 100 dan 200 ng), fenilefrina (0.25, 0.5, 1 dan 2 J.l.g) and 
metoksamina ( 1, 2, 3 dan 4 J.l.g) tanpa dan dengan kehadiran antagonis ditentukan 
Antagonist yang digunakan ialah nitrendipina ( suatu penghambat terusan Ca ++ 
jenis-L), 5-metilurapidil (suatu antagonis adrenoseptor-a.IA), kloroetilklonidina 
(suatu agen pengalkilasi adrenoseptor-a.18) and BMY 7378 (suatu antagonis 
adrenoseptor-a.m). Data dianalisa dengan ANOV A tiga faktor untuk RBF dan 
ANOV A dua faktor untuk parameter-parameter yang lain, dan nilai purata ± s.e.m. 
dibandingkan dengan menggunakan "multi range "t" test" dan dianggap signifikan 
pada paras 5%. 
Keputusan menunjukkan bahawa kadar glukosa plasma, "nilai basal" dari 
pada tekanan darah nilai purata (MAP) and RBF pada tikus SD diabetik adalah 
291.5 ± 13.0 mgldl, 122 ± 6 mmHg and 26.5 ± 3.0 ml/kgl min dan pada tikus 
bukan diabetik adalah 118.0 ± 4.8 mgldl, 122 ± 8 mmHg and 24.6 ± 1.8 
ml/minlkg. Pada tikus SHR diabetik, nilai tersebut adalah 316.2 ± 10.5 mgldl, 
144 ± 12 mmHg and 27.0 ± 4.1 ml/kglmin dibandingkan dengan tikus bukan 
diabetik di mana nilai 112.3 ± 4.7 mg/dl, 156 ± 24 mmHg and 28.1 ± 2.6 
mVkglmin diperolehi. Selanjutnya, pada tikus 2K 1 C di~hetes, nilai kadar glukosa 
darah, "nilai basal" MAP dan RBF adalah 298.0 ± 11.6 mgldl, 125 ± 6 mmHg dan 
27.7 ± 4.2 mVkglmin sedangkan pada tikus 2K1C bukan d_@betik nilainya adalah 
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113 ± 5.3 mg/dl, 144.3 ± 3 mmHg dan 28.9 ± 1.2 mllkg/min berturut-turut. 
Respons vasokostriktor ginjal menunjukkan bahawa pada tikus SD, SHR dan 
2K1C bukan diabetik, respons vasokonstriksi ini dimediasi oleh adrenoseptor 
subjenis a1A- dan am- tetapi dalam tikus SD dan 2K1C diabetik adalah 
adrenoseptor a1A. sedangkan dalam tikus SHR dan oleh adrenoseptor subtipe alA-
dan am- pada tikus SHR diabetes. Terdapat kemungkinan terlibatnya adrenoseptor 
pre-sinaps (samada a 18, a 1L atau a 2) pada tikus SHR. dan 2K1C diabetes dalam 
memediasi vasokonstriksi pembuluh darah di ginjal. 
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ABSTRACT 
Diabetes mellitus could trigger the development of damage of small and 
large caliber blood vessels and peripheral nerves; wich greatly increasing the risk 
of heart attack, stroke, blindness, amputation and renal failure (Porte and Schwartz, 
1996), and hypertension exacerbate these alterations (Todd et al., 1993). a.I-
adrenoceptors are known to play an important role in the vasoconstrictions in 
response to adrenergic stimulation. However, there is no information about the 
functional importance of a.1-adrenoceptor subtypes in the renal vascular resistance 
in diabetes. This study sets out to examine the role a.1-adrenoceptor subtypes by. 
comparing the vasoconstrictor responses to different adrenergic stimulations in the 
presence and absence of several antagonists in the kidney of diabetic and 
hypertensive rats. 
Sprague Dawley (SD), spontaneously hypertensive rats (SHR) and two 
kidney one clip (2K1C)-Goldblatt hypertensive rats were used. Streptozotocin (55 
mg/kg, ip) was utilized to induce diabetes and rats were used 7 days post treatment. 
The body weight (BW), water intake (\VI), urine output (UO), the plasma glucose, 
sodium and creatinine levels, 24-hour sodium and creatinine excretion were 
measured. After anaesthesia (pentobarbitone, 60 mglkg, i.p.), the rats were 
prepared for the blood pressure measurements. Left kidney was exposed via a 
midline abdominal incision, and an electromagnetic flowmeter probe was fitted on 
the renal artery for blood flow measurements. The renal nerve was identified, 
sectioned and placed on bipolar stimulating ele:trodes. The renal blood flow 
(RBF) to direct renal nerve stimulation (RNS) at 1, 2, 4, 6, 8 and 10Hz at 15mV 
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and 2 millisecond for 20 seconds) and administration of adrenergic agonists 
noradrenaline (25, 50, 100 and 200 ng), phenylephrine (0.25, 0.5, 1 and 2 J.Lg) and 
methoxamine (1, 2, 3 and 4 J.Lg) in the absence and presence of the antagonists were 
determined. The antagonists used were nitrendipine (an L-type Ca ++ channel 
blocker), 5-methylurapidil (an alA -adrenoceptor antagonist), chloroethylclonidine 
(an alpha1B-adrenoceptor alkylating agent) and BMY 7378 (an alpha 1D-
adrenoceptor antagonist) were utilized. Data were analyzed using three way 
ANOV A for RBF, and two way AN OVA for the rest of the parameters, and the 
means ± s.e.m. were compared with multi range "t" test and Duncan's Post-Hoes 
test, and the significance taken at the 5% level. 
Results showed that plasma glucose, basf."-line MAP and RBF in diabetic 
SD rats were 291.5 ± 13.0 mg/dl, 122 ± 6 mmHg and 26.5 ± 3.0 ml/kg/ min 
respectively and in non-diabetic rats the values were 118.0 ± 4.8 mg/dl, 122 ± 8 
mmHg and 24.6 ± 1.8 ml/minlkg respectively. In diabetic SHR these values were 
316.2 ± 10.5 mg/dl, 144 ± 12 mmHg and 27.0 ± 4.1 ml/kg/min respectively as 
compared to non-diabetic SHR 112.3 ± 4. 7 mg/dl, 156 ± 24 mmHg and 28.1 ± 2.6 
mllkg/min respectively. In the diabetic 3K1C rats, the values of blood glucose 
level, base-line MAP and RBF were 298.0 ± 11.6 mg/dl, 125 ± 6 mmHg and 27.7 ± 
4.2 mllkg/min respectively, whereas in non-diabetic 2K1C rats these values were 
113 ± 5.3 mg/dl, 144.3 ± 3 mmHg and 28.9 ± 1.2 mllkg/min respectively. Renal 
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vasoconstrictor responses measurements indicated that in non-diabetic SD, SHR 
and 2KlC rats, these vasoconstrictions are mediated by a1A- and am-
adrenoceptors, but in the diabetic SD and 2KIC rats it is mediated by a1A-
adrenoceptors and by a 1A- and a 10-a.drenoceptors in the diabetic SHR. 
XX1 
Furthennore, evidence has been obtained showing the involvement of pre-synaptic 
(either a.m, O.IL or a.2 -) adrenoceptors in diabetic SHR and 2K1C rats in the 
mediation of the renal vasoconstrictions. 
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CHAPTER I 
INTRODUCTION 
1.1. Receptors 
To produce biological effects, most drugs, hormones and neurotransmitters 
interact with receptors. Receptors are described as various recognition sites at 
which drugs act (Williams et al., 1995). This concept was first des~ribed in the 
earlier nineteenth century based on an observation of the extraordinary potency and 
specificity of some drugs that mimicked a biological response (agonists) ·while 
others inhibited it (antagonists). Later, Clark (1933), independently described the 
quantitative characteristics of competitive antagonism between agonists and 
antagonists in combining with specific receptors in intact preparations. This 
receptor concept has been substantiated by isolation of macromolecule substances 
that fit all the criteria of being receptors. To date, receptors have been identified for 
all the proven neurotransmitters as well as for histamines, opioid peptides, 
neurotensin, bradykinin, angiotensin etc., although all of them have not been cloned 
(Cooper et al., 1996). 
Multiple receptors have been shown to co-exist for all the biogenic amines, 
acetylcholine, GABA, histamines, opiates, the amino acids transmitters and others. 
These receptors appear to metastasize at an uncontrollable rate, but it should be 
viewed doubtfully until a physiological response to the ligand has been shown or a 
specific gene has been cloned and expressed. Currently, the research for receptors 
is amongst the most intensively investigated area in neurosciences. Identification of 
adrenergic, dopaminergic, muscarinic, serotoninergic and histaminergic receptor 
subtypes has lead to the synthesis of highly specific drugs that are considerably more 
specific than their prototypes which were developed after general screening for 
activity. As in gene cloning and expression, more and more receptor subtypes are 
being identified, each presumably having its own function. This lead to the design 
of future drugs that fit with a single receptor s·.~btype, thus precluding what are 
called the side effects of non-specific drugs. Most of the receptors are located on 
the surface of the cell, except receptors for steroids and thyroid hormones, which 
are localized intracellularly (Cooper, et al. 1996). 
For many secreted transmitters, there are receptors on the presynaptic as 
well as on the postsynaptic elements. The presynaptic receptors serve as auto-
receptors or heteroreceptors. Autoreceptors can facilitate or inhibit the release of 
neurotransmitters (Langer, 1997; and Ganong, 1999). The inhibition of 
neurotransmitter release mediated by autoreceptor was originally based on several 
findings. Firstly, the Ca2+ dependent release of neurotransmitter triggered by the 
action potential was inhibited by receptor agonists. Secondly, antagonists on their 
own, enhanced neurotransmitter release and finally interaction between agonists and 
antagonists that modulate transmitter release was of competitive nature. The 
presynaptic heteroreceptors are the second category of presynaptic receptors that 
modulate neurotransmitter release, as a response to the presence of chemical signals 
in the synaptic cleft other than the neurone's own transmitter. 'fhese presynaptic 
heteroreceptors are sensitive to cotransmitter neuropeptides, transmitter releases 
from adjacent terminals or other substances that are already produced or blood 
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borne, that either facilitate or inhibit the release of the neurotransmitters (Langer, 
1997). 
Receptors are dynamic in nature and undergo both ligand and gene related 
control throughout their life (Hollenberg et al., 1985). The turnover of the 
receptors occur as a consequence of the growth with a halflife that varies between 
hours to days (Mahan et al., 1987). Ligand occupancy can also alter the receptor 
density. Hence, the neurotransmission and neur~modulation processes are under 
tonic control. The molecular basis of many disease states may thus reflect an 
increase or a decrease in the stimulation of a given receptor system. This inequity in 
tum may reflect over or under production of the endogenous ligand, a decrease in 
receptor density or function, a persistence in activation due to maladaptation of the 
transduction system etc. (Williams et al., 1995). The accumulation of evidence for 
the association of specific receptor density changes with specific disease states has 
been a major goal of biomedical research over the past two decades. Thereby 
molecular mechanisms involved in the disease process can be identified and used for 
drug targeting and disease diagnosis (Williams et al., 1995). 
1.1.1. Receptor Assays 
The interaction of neurotransmitters, hormones and drugs with cells can be 
determined as follows: 
1. By determining the biological responses of an intact isolated organ such as 
guinea pig ileum to the applied agonists or antagonists. The disadvantage of 
using this method is that the effect of cascade events beginning with transport, 
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distribution, metabolism of the agent before it interact with receptors and give 
responses are avoided (Cooper et al., 1996). 
2. By measuring ligand binding to a homogenated or slice preparation using highly 
specific radioactive ligand with high affinity for the receptors. This can be done 
directly or indirectly, by incubating receptor preparation with labeled agonist I 
antagonist. The receptor-ligand complex is then separated from the free ligand 
by centrifugation, filtration or precipitation , by using equilibrium dialysis in 
which the receptors-ligand and complex is determined by subtracting the ligand 
concentration in bath from that of the dialysis sac respectively (Cooper et al., 
1996). 
3. Through molecular biological studies using the recombinant DNA (rDNA) 
technology. This technique requires the isolated DNA encoding the protein of 
interest from the library of complimentary DNA sequences. Once cloned and 
identified, the nucleotide sequence of the receptor gene can be determined and 
this allows the primary structure of isolated receptor to be deduced. The ability 
of a drug to alter the structure of cloned receptor specifically through 
modification of small number of nucleotides is a standpoint of drug discovery 
(William et al., 1995). 
4. By using the electrophysiological techniques in which the receptor subtype(s) is 
fractionally identified by the intracellular stimulation and recording via 
microelectrodes which are inserted into brain slice or neurons in culture 
combined with the application of receptor agonists and antagonists (Cooper et 
al., 1996). 
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5. By using macromolecular crystallography technique. This technique is based on 
the ability of a molecule to scatter the X-ray and the geometry of scattering is 
governed by Bragg's law nA. = 2dsin9, where n is a positive interger, A. is the 
wavelength, d is the spacing of plane in the crystal and the 9 is the angle of 
incidence to the plane. Generally, the macromolecule is highly purified (better 
than 99%) before determination and then crystallized (Oakly and Wilce, 2000). 
1.1.2. Adrenergic Receptors 
Adrenergic receptors ( adrenoceptors) are receptors that mediate the central 
and peripheral action of primary sympathetic neurotransmitters noradrenaline and 
the primary adrenal medullary hormone (and central transmitter) adrenaline. 
Adrenoceptors are found in most of the peripheral tissues and in many neuronal 
populations within the central nervous system. These adrenoceptors mediate a 
variety of functions, such as blood pressure, myocardial contractile rate and force, 
airway reactivity, and an array of metabolic functions. Several types of neuronal 
varicosities also have prejunctional (presynaptic) adrenoceptors serving as auto or 
heteroreceptors that inhibit or modify nerve-evoked release of several 
neurotransmitters (Bylund, et al., 1994). 
There are multiple, closely related adrenoceptor subtypes, although their 
~xact number and the appropriate mode of grouping into major families is still 
:;ontroversial. Generally, current knowledge classifies the adrenoceptors into three 
najor subtypes, called ex.~, cx.2 and P-adrenoceptors (Bylund, et a/.1994). This sub-
:;lassifications are based on several functional, molecular and radioligand binding 
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studies after several considerations. Firstly, the different maJor types of 
adrenoceptors affinity for selective drugs is 3 to 4 orders of magnitude (i.e. CX.1, cx.2 
and ~), and the affinity ratio for each major subtype is only between 10 to 100. 
Secondly, the second-messenger responses of each major subtype are different and 
finally, that the predicted amino acid sequences of the adrenoceptors are more 
consistent with three rather than two major types (Bylund, 1992). These three 
subtypes are further sub-classified into several subtypes, cx.lA, cx.1B, cx.m, and cx.1L, cx.2A, 
CX.2B, CX.2c, and cx.20, and ~1. ~2 and ~3 (Bylund eta/., 1994; Cooper, 1996; and Zhong 
and Minneman, 1999). 
1.1.2.1. cx.1-adrenoceptors 
cx.1-adrenoceptors exist as a heterogenous family. More than a decade ago, 
pharmacological studies indicated the existence of cx.1A- and cx.1B-adrenoceptors 
(Morrow and Greese, 1986; Han, eta/., 1987; and Minneman, 1988). More recent 
studies by molecular cloning technique have exposed the co-existence of cx.1a-, cx.1b-, 
and cx.wadrenoceptors. The development of adrenoceptor researches, based on 
pharmacological and molecular studies have indicated that these cloned subtypes 
correspond to native cx.lA-, cx.lB- and cx.10- adrenoceptor subtypes (Ford, eta/., 1994; 
Bylund et a/., 1995; and Hieble eta/., 1995). Functionally, these receptors were 
characterized by their high affinity for prazosin (previously called cx.m) and low 
affinity for yohimbine (Bylund, et aL; 1994). Other subtype (if any) with a low 
affinity to prazosin i.e. the cx.1L, has been postulated to mediate contractions in some 
tissues (Flavahan and Vanhoutte, 1986; Muramatsu et al., 1990; Oshita eta!., 1991; 
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Ford et a/., 1996; and Zhong and Minneman, 1999), but its relationship to cloned 
receptors remains to be established (Bylund et al, 1998). This receptor is more 
prominent in the human, rabbit and dog urethra and in the dog and human prostate 
(Fukasawa et a/., 1998; and Langer, 1999), and is also suggested to mediate the 
contraction of canine pulmonary artery (Flavahan et al., 1998). 
cx.1-adrenoceptor subtypes are widely expressed in different neonatal and 
adult rat tissues. High levels of cx.1A- and cx.10-adrenoceptors were detected in brain 
and heart whereas similar levels of cx.1B-adrenoceptor in liver and heart of neonatal 
rats by immunoreactive mechanism. In adult rat tissues, cx.1A-adrenoceptors protein 
were most marked in the brain, intermediate in heart, aorta, liver, vas deferens and 
adrenals, and minimal in the kidney and prostate as compared to other tissues. The 
expression of cx.1B-adrenoceptors was higher in the brain and heart but the 
expression of cx.10-adrenoceptors in brain was most prominent (Shen et al., 2000). 
cx.1-adrenoceptor subtypes are localized in different parts of the cell. CX.lA-
adrenoceptor subtypes for example, are localized in a perinuclear fashion, whereas 
cx.1B-adrenoceptor subtype was detected throughout the entire border of the cell 
(Hirasawa et al., 1997). Further studies on the vascular smooth muscle cells did not 
indicate that the cx.1A- and cx.10-adrenoceptor subtypes were defined on the cell but 
that the cx.1-adrenoceptor subtypes were found in the intracellular compartment 
(Hrometz et al., 1999). 
All cx.1-adrenoceptor subtype§. are activated by the sympathetic neuro-
transmitters, noradrenaline and adrenaline, even though none of these catechol-
amines exhibit selective affinity to any of these adrenoceptor subtypes. cx.1-
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:drenoceptor mediated responses are blocked by prazosin and showed a low affinity 
or selective a2-adrenoceptor antagonists such as yohimbine or rauwolscine. These 
eceptors can be labeled with eH) prazosin or C25I)ffiE-2254, and activation of 
~ch subtype is associated with an increase in intracellular calcium concentration 
Bylund et al., 1994). a1A-adrenoceptor has a higher affinity for 5-methylurapidil 
Ford et a!., 1994; Michel and Insel, 1994; Perez, et a!., 1994; and Testa et al., 
l995), KMD-3213 (Shibata et al., 1995), S(+) niguldipine (Boer et al., 1989; and 
•ord et al., 1994), benoxathian (Han eta!., 1987) and oxyrnetazoline (Ford eta!., 
l994), as compared to the other two subtypes. Dapiprazole seems to be moderately 
;elective (approximately 10-fold) for the A an.:: D over the B subtype of a1-
tdrenoceptors (Eltze, 1997). BMY 73 78 (8-[2-[ 4-(2-methoxyphenyl)-1-pipera-
dnyl]ethyl]-8-azaspiro[ 4. 5]decane-7, 9-dionedihydro chloride )(Saussy, 1994; Goetz 
~~a!., 1995; and Kenny, 1995) and SKF 105854 (Hieble, et al., 1995) possess a 
ligher affinity for am subtype or cloned human am-adrenoceptor. The am-
tdrenoceptor is relatively resistant to alkylation by chloroethylclonidine ( CEC) and 
1as a low affinity for 5-methylurapidil and (+)niguldipine (Ford et al., 1994). The 
x.IB-adrenoceptor (previously called a 1b) subtype is most sensitive to be alkylated by 
:EC (Minneman eta!., 1988; and Bylund et al., 1994), risperidone (Sleight eta!., 
993; and Ford et al., 1994) and spiperone (Michel eta!., 1987; and Ford et al., 
994). Buspirone, like its close analogs, BMY 7378 and MDL 73005EF, may also 
1e a useful tool for functionally discrirninati~$ am- from alA-, a1B- and a1L-
drenoceptors in various tissues. This compound is a weak antagonist without an 
1trinsic activity towards a 1A-adrenoceptors in the rat vas deferens, alB-
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. adrenoceptors in guinea-pig and mouse spleen l!:'!d towards a.1L-adrenoceptors in 
. rabbit spleen. Buspirone also caused a partial vasoconstriction in the rat kidney that 
was attenuated by the a.m-adrenoceptors antagonist BMY 73 78, but hardly by the 
a.1A-adrenoceptors selective antagonist, B880 5-03 3 ( (+I-)-1 ,3, 5-trimethyl-6-[[3 -[ 4-
( (2,3-dihydro-2-hydroxy-methyl)-1, 4-benzodioxin-5-yl)-1-piperazinyl] propyl] 
amino] 2,4 1H, 3H)-pyrimidinedione). Furthermore, Buspirone behaved as a partial 
agonist towards a.m-adrenoceptors in the rat aorta and pulmonary artery (Eltze, 
1999). 
The new native and cloned classification of a.1-adrenoceptor subtypes and 
their historical cloned nomenclature are shown in Table 1.1. 
Table 1.1. Nomenclature for a.1-adrenoceptor subtypes 
Native Cloned (New nomenclature) Cloned (historical nomenclature) 
0.JA 0.1a O.!c 
a.lB a.lb O.tb 
a.m a.ld 0.1a, 0.Jd, 0.1a1d 
0.1L ? ? 
(Ford et al., 1994; and Hieble et al., 1995) 
All a.1-adrenoceptor subtypes activate phospholipase C (Schwinn et al., 
1991; and Perez et al., 1993) through the G(q/11) family of G proteins (Wu et al., 
1992), release stored Ca2-, a~d activate protein kinase C (Zhong and Minneman, 
1999) and inositol phosphate turnover (Docherty, 1998), although with significant 
differences in coupling efficiency (a.1A > a.18 > a.10). Other second messenger 
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pathways are also activated by these receptors, including Ca2+ influx (Han et al., 
1992; Sayet et al., 1993; Lazou et al., 1994; and Minneman and Esbenshade, 1994), 
arachidonic acid release, and phospholipase D activation. The a.t-adrenoceptor-
induced vasoconstriction appears to be caused both by the release of intracellular 
calcium and by the transmembranous influx of extracellular calcium (Caufin and 
Malik, 1984; Bylund et al., 1994; and Zhong and Minneman, 1999). The ratio 
between both of these processes is very different, depending upon the type of a.t-
adrenoceptor agonist and on the experimental preparations used (V an-Zwieten and 
Timmermans, 1987). a.1-adrenoceptors also activate mitogen-activated protein 
kinase pathways in many cells, although some of these responses are independent of 
Ca ++ and protein kinase C and involve small G prm:eins and tyrosine kinases. Direct 
interactions of a.1-adrenoceptors with proteins other than G proteins have not yet 
been reported. However there is a consensus for the binding motive of the 
immediate early gene Homer in the C-terminal tail of the a.10 subtype (Zhong and 
Minneman, 1999). 
a.1-adrenoceptors involve rapid processes such as sequestration and slower 
processes such as receptor down-regulation ( Garcia-Sainz, 1993; and Cotecchia et 
al., 1995). The slower down-regulation of these receptors may be related to the 
pathophysiological processes which occur in disease states such as cardiac failure 
and chronic renal failure (Packer, 1992). Accordi)lg to Dong and Han (1995), a.1B-
adrenoceptor mediated vasoconstriction is easier to be desensitized, while a.IA-
adrenoceptor mediated constriction is easier to be hypersensitized. Furthermore, 
both a.1A- and a.10-adrenoceptor subtypes are functionally upregulated in 
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spontaneously hypertensive rat (SHR) muscle vascular bed. This may provide some 
clues for the possible role of a.1-adrenoceptor subtypes in the maintenance of 
elevated blood pressure (Y e and Colquhoun, 1998). 
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Functional expression of a.10-adrenoceptors in the rat resistance vessels 
increases with age; a.1A-, but not a.1B- or a.10-adrenoceptors, seems to predominate 
in immature animals. This represent the evidence that age-related changes in 
functional a.1-adrenoceptor subtypes occur in the systemic vasculature in vivo 
(DeOliveira et al., 1998; Ibarra et al., 1999; and Villalobos-Melina et al., 1999). 
The steady state levels for a.1A-, Cl1B"" and a.10-adrenoceptors in aorta declined with 
maturation and aging. In the renal artery, there was a decrease in mRNA for the 
a.1B-adrenoceptor in aged rats. However, in mesenteric and pulmonary arteries 
there were no changes in mRNA levels for the three subtypes of a.1-adrenoceptors 
as a result of maturation and aging (Xu, et al. 1997). In addition, all the three 
receptor subtypes increased with age in the brain cortex, whereas the density of a.lB-
adrenoceptor increased in the heart but decreased in the liver. Furthermore, a.1A-
and a.m-adrenoceptors population in liver, kidney and heart of rats were not 
affected by age (Shen, 2000). 
1.1.2.2. a.2-adrenoceptors 
a.2-adrenoceptors can be pharmacologically divided into a.2A-, a.2B-, a.2c- and 
a.2D-adrenoceptors, all of which mediate contractile \esponses (Cooper, 1996; 
Docherty, 1998; and Zhong and Minneman, 1999). All subtypes can be blocked by 
yohimbine and rauwolscine and labeled with 3H analo&~ of these antagonists, 
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although the affinity varies substantially between the subtypes (Bylund et al., 1994). 
a.2A-adrenoceptor subtype is characterized by its low affinity, and conversely, a2B-
subtype by its high affinity to prazosin (Bylund and Ray-Prenger, 1989). a2A-
adrenoceptors are selectively inhibited by BRL44408, while a2B by ARC 239, 
spiroxatrine and imiloxan (Young et al., 1989). a 2c-adrenoceptor is typically 
similar to a2B-subtype. It has a relatively high affinity for prazosin, ACR 239 and 
spiroxatrine, but a higher affinity for rauwolscine. Other antagonists which are 
selective for a2-adrenoceptor subtype are BAM 1303 and WB4101 (Bylund, 1994). 
The a20-adrenoceptor subtype has a low affinity for CH)rauwolscine than the other 
subtypes, low affinity for prazosin, spiroxatrine and ARC 239, but moderately 
selective for BAM1303 (Simonneaux et al., 1991). It is presumed that the rat a20-
adrenoceptor subtype is a human a 2A-adrenoceptor subtype homologue (Bylund et 
a/., 1994). 
The a2-adrenoceptors can be pre- and postjunctional. Some of the 
prejunctional aradrenoceptors are neuroinhibitory in their action (Bylund, 1988; 
Akers et al., 1991; and Oriowo et al., 1991). Prejunctional inhibitory a2-
adrenoceptors are predominantly of the a 2A-adrenoceptor subtype (the a20-
adrenoceptor is a species orthologue). Furthermore, a 2c-adrenoceptors may also 
occur prejunctionally (Docherty, 1998). Although a 2-adrenoceptors are linked to 
inhibition of adenylate cyclase (Bylund et a/., 1994), this may not be the primary 
signal in causing smooth muscle contraction. Pt:ejunctional inhibitory actions 
probably involving the restriction of Ca2+ entry -or the opening of K.,. channels 
(Docherty, 1998). 
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1.1.2.3. Beta Adrenoceptors 
Previously, two ~-adrenoceptor subtypes were known to exist i.e. ~~-and ~z-
adrenoceptors (Lands eta!., 1967). The subtype-selective agonists, antagonists and 
therapeutic application of several of these pharmacological classes have been 
developed. Further and later studies have successfully identified ~3-adrenoceptor 
subtype using selective agonists and recombinant receptor expression (Bylund et a!., 
1994). The pharmacological characteristics of the recombinant receptors appear to 
correspond well with those of the three receptor subtypes identified in native 
tissues, although there are some differences in the case of the ~3-adrenoceptors. 
Endogenous catecholamines, adrenaline and noradrenaline are equipotent to 
~~-adrenoceptor with adrenaline having a 1 00-fold selectivity for ~2-adrenoceptors. 
Conversely, noradrenaline is more potent than adrenaline as a ~3-adrenoceptor 
agonist. Propranolol and many of its analogs are potent antagonists of f3t- and f32-
adrenoceptors. However, ~3-adrenoceptors seem to be less sensitive to these 
antagonists (Bylund et a!., 1994). Both f3 1-adrenoceptor and f32-adrenoceptors can 
be labeled with eH)dihydroalprenolol or C25I)iodopindolol and its analogs, while 
~3-adrenoceptors, although can be labeled with C25I)iodocyanopindolol, has a 10-
fold lower affinity compared to f3 1- and f3z-adrenoceptors (Emerine et al., 1992). 
All of the three ~-adrenoceptor subtypes activate adenylyl cyclase as a primary 
mechanism for signal transduction (Bylund eta!., 1994). 
f31-adrenoceptors mediate the inc~eases in cardiac rate and force of 
' 
contraction, stimulation of renin secretion, relaxation of coronary arteries and 
relaxation of gastrointestinal smooth muscles ...... ~2-adrenoceptors mediate smooth 
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t~ muscle relaxation at many sites, including airways, most blood vessels and uterus. 
t~:~ 
The prejunctional f32-adrenoceptors modulate noradrenaline release from the 
sympathetic nerve terminals (Bylund et al., 1994). 
1.1.3. a.1-adrenoceptors in Vasculature 
The a.1-adrenoceptors, component of the sympathetic nervous system, is 
involved in the regulation of cardiovascular function, ·and its subtypes are 
heterogeneously distributed in various vessels (Kohno et al., 1994). The differences 
in a.1-adrenoceptor population and distribution depend on the blood vessel and the 
pathological state (LeTran and Forster, 1997). Arterial vasoconstriction in the rat is 
primarily mediated by a.1-adrenoceptors (Ohyanagi et al., 1991; Vargas and 
Gorman, 1995). The genes encoding the a.1. adrenoceptors are widely expressed in 
the heart and peripheral arteries (Perez et al., 1994; Piascik et al., 1995; Guarino et 
al., 1996) and this has been shown by a variety of functional studies (Han et al., 
1990; Elhawary et al., 1992; Bylund et al., 1995; Kenny et al., 1995; Piascik et al., 
1995; Testa et al., 1995; Leech and Faber, 1996; Zhou and Varga, 1996). As 
discussed earlier, a.1-adrenoceptors comprises of a.1A-, <liB-, am- and a.1L-
adrenoceptor subtypes and recent studies indicate that the rat vascular smooth 
muscle can express mRNAs for the a.1A-, alB- and a.10-adrenoceptors besides a2B-, 
and a.w-adrenoceptors (Leech and Faber, 1996). 
Although a.1-adrenoceptors are widely distributed, certain receptors are not 
link to mediating contraction in a majority of arteries in which they are expressed. 
' 
In other words, receptors can be expressed but may not necessarily participate in the 
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contractile regulation (Hrometz eta/., 1999). As an example, the p53 knockout 
mice aortic smooth muscle line contains predominantly cx.18-adrenoceptors and a 
small population of cx.10-adrenoceptors. However, phosphoinositide/Ca2+ signaling 
of this cell line is mainly mediated through the minor population of cx.m-
adrenoceptors (Ohmi, 1999). 
According to Zhou and Vargas (1996), cx.10-adrenoceptors mediate vascular 
smooth muscle contraction in vivo, but further studies indicated the involvement of 
different cx.1-adrenoceptor subtypes in a variety of vessels. According to Stassen et 
a/ (1998), there is a reversible positive relationship between the presence of 
adrenergic nerves and that of cx.1A-adrenoceptor in rat arteries. 
The guinea pig and rabbit aorta contractions are mediated by CX.1L-
adrenoceptors (Oshita eta/., 1993; Kenny eta/., 1995; Brackner eta/., 1996; and 
Yamamoto eta/., 1999) and cx.10-adrenoceptors (Piascik eta/., 1995), while the rat 
aorta contraction are mediated by a.18-adrenocep~ors (Testa et a/., 1995) and a.m-
adrenoceptors (Hussain eta/., 1997). However, Satoh eta/. (1999) reported that 
there is no indication of cx.10-adrenoceptors involvement in either thoracic or 
abdominal aorta and in the aortic smooth muscle line (Ohmi, 1999). 
The contraction of bovine carotid and vertebral arteries are mediated by cx.m-
adrenoceptors (Kohno et a/., 1994), whereas that of rat femoral artery is mediated 
by a.m-adrenoceptors (Hrometz et a/., 1999) or cx.1L -adrenoceptor (Kohno et a/., 
1994). The contraction of rat iliac artery is mediated by a.10-adrenoceptors (Kenny 
eta/., 1995; Piascik eta!., 1995; and Satoh eta!., 1999), and that of the rat small 
mesenteric artery by cx.1L-adrenoceptors (Starn, 19,99; and Yamamoto eta!., 1999), 
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r ~ or a.1A-adrenoceptors (Kong et al., 1994; and Zhu et al., 1999). Furthermore, the 
~ .... f contraction of rat and human vas deferens is mediated by a.1A-adrenoceptors 
... 
~- (Fukuwara, et al., 1995; and Henner and Docherty, 1999), porcine coronary artery 
~ 
by a.1A-adrenoceptor (Yan et al., 1998), the hind limb and skeletal muscle by a.1A-
adrenoceptors (Zhu et al., 1997). 
The rabbit's ear microvasculature has a heterogenous distribution of a.1-
adrenoceptor subtypes. The a.1A and a.10-adrenoceptor subtypes appear to have a 
greater influence on constrictive function in the rabbit ear arterioles, whereas the 
a.m-adrenoceptor is the dominant constrictor- of arteriovenous anastomoses (Li et 
al., 2000). The creamaster skeletal muscle arterioles constriction are suggested to 
be mediate by cx.m-adrenoceptor subtypes while the venules by cx.m-adrenoceptors 
(Leech and Faber, 1996). 
1.1.4. a.1-adrenoceptors in the kidney 
Multiple adrenoceptor subtypes have been shown to exist in the kidney 
(Minneman et al, 1988; Han et al, 1990; and Feng et al., 1991). The density of a1-
adrenoceptors is highest in the cortex and decreases from the cortex to papilla. The 
proportion of a.1A- and a.1B-adrenoceptors is alm?st equal in the cortex and outer 
stripes of the outer medulla, but with the am- subtype predominating in the inner 
stripe of the outer medulla, whilst at the proximal tubules they are expressed at 
approximately equal levels (Feng et al., 1991). 
A recent study by Kurooka et al. (1999) described that three a.1-
adrenoceptor subtype mRNAs were recognized in human renal cortex and detected 
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particularly m the smooth muscles of the arteries. There were more a.1A-
adrenoceptors subtype in human renal cortex than the other subtypes. Expression 
of the three a.1-adrenoceptor subtypes mRNAs were confirmed in the arteries of the 
renal cortex (arciform, interlobular, arteriole), but among the three subtypes, the a.1B 
was less apparent by in situ hybridization. Intense a.1-mRNA staining was apparent 
especially in the smooth muscle of the arterial walls of the kidney. In both proximal 
and distal renal tubules, each of the a.1-mRNAs was less marked in cytoplasm than 
in the arteries. In the glomeruli, weak staining was detected in the endothelium but 
there was no obvious staining in the vein. Reverse transcryptase-polymerase chain 
reaction (RT-PCR) showed all three subtypes of a.1-adrenoceptor in the rat renal 
cortex. Similarly, Moriyama et al. (2000) studies using the RNase protection assay 
showed that the predominant a.1-adrenoceptor subtype mRNA in human renal 
cortex was a.IA· Furthermore, these authors described that the mean amount of a.1A 
mRNA was much greater than that of a.IB or a.10 mRNAs in both the main and 
branched renal arteries using RNase protection assay. In situ hybridization showed 
that all a.1 subtype mRNAs were localized in the smooth muscle cells of the tunica 
media of the artery, and the distribution pattern of these three mRNAs in the main 
artery was the same as in the branched artery. However, the intensity of signals for 
a.m- and a.IB- antisense RNAs probes were lower than that for the a.1A- probe. 
Furthermore, functional study demonstrated that the a.1uA-adrenoceptor mediates 
primarily the responses to noradrenaline in this artery (Moriyama et q,l., 2000). 
Vasoconstrictor responses to noradrenaline in the isolated perfused kidney 
of the rat are mediated by a.1-adrenoceptors (Schmitz et al., 1981). Further studies 
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by Blue et a/. (1995) usmg the same preparation demonstrated that a1A-
adrenoceptor is the predominant a1-adrenoceptor subtype mediating vasoconstrictor 
responses to exogenous administration of noradrenaline. In the intact rats, 
activation of a1A-adrenoceptors caused constriction of the renal vascular resistance 
bed (afferent and efferent arterioles) and induces antinatriuresis and antidiuresis. 
This situation was seen in the Wistar, Stroke-Prone Spontaneously Hypertensive 
rats (SPSHR), two kidney one clip (2K1C) and,deoxycorticosterone acetate-Salt 
(DOCA-Salt) hypertensive rats (Sattar and Johns, 1994a and b). Moreover, these 
authors showed that the a1B-adrenoceptor subtype seems to play a lesser role in 
mediating similar responses. These findings are supported by a more recent study 
showing that the a1A-adrenoceptor is the major subtype in renal resistance arterioles 
(Zhu et al., 1997). It has also been reported, that the renal adrenergic 
vasoconstrictor responses are mediated by a 1A- (Blue et al., 1992; Elhawari et a/, 
1992; Eltze and Boer, 1992; Blue eta/, 1995; Eltze et al., 1994; and Villalobos-
Molina and Ibarra, 1997) and or via a 10-adrenoceptor subtypes (Villalobos-Molina 
and Ibarra, 1996 and 1997), although Piascik et a/. ( 1995), provided evidence 
' 
showing that the am-adrenoceptors did not play a role in mediating the contractions 
in this vessel. However, a later study by Eltze (1999) and Satoh et a/., (1999) 
indicated the presence and involvement of a 10-adrenoceptors in mediating the rat 
renal vasoconstriction. 
_:. 
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1.2. The Kidney 
1.2.1. Anatomy 
The kidneys are a pair of encapsulated organs located in the retroperitoneal 
area and consists of two parts i.e., the cortex and medulla. Renal medulla is made 
up of outer and inner medulla that protrudes towards the renal pelvis (Muirhead, 
1984). The cortex forms the renal columns through which passes the renal vessels, 
(Lumley et al., 1996) i.e., interlobar and arcuate arteries (Basar and Weis, 1981) 
(Figure 1.1). The functional unit of the kidneys is the nephron, which comprises 
of glomerulus and tubule and each human kidney contains approximately 1.3 
million nephrons. The size of the kidney is determined largely by the number of 
nephrons they contain (Ganong, 1999). 
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Figure 1.1. Structure of the kidney (A), nephron (B) and glomerulus (C) (Adopted 
i:. from Folkow and Neil, 1971) 
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1.2.1.1. Glomerulus 
The glomerulus is about 200 J.Uil in diameter and formed by an invagination 
of a tuft of capillaries into the dilated, blind end of the nephron i.e. the Bowman's 
capsule. The capillaries are supplied by an afferent arteriole and drained by an 
efferent arteriole. In Bowman's capsule, the blood from the glomerular filtrate is 
separated by two cellular layers, called the capillary endothelium. These two layers 
are separated by a basal lamina. Between the basal lamina and the endothelium 
there are stellate cells known as mesangial cells which are common between two 
neighbouring capillaries, and forms a sheath shared by both capillaries (Ganong, 
1999; and Junqueira et al., 1999). These cells are contractile (Ganong, 1999) and 
play a role in the regulation of glomerular filtratio1:. (Ganong, 1999; and Junqueira et 
a!., 1999). They also secrete a number of substances and are involved in 
glomerular diseases (Ganong, 1999) such as glomerulonephritis, IgA nephropathy, 
diabetic nephropathy etc. (Lingappa, 1997). 
The endothelium of the glomerular capillaries is fenestrated with pores that 
are 70 - 90 nm in diameter. Epithelium cells (podocytes) have numerous 
pseudopodia that integrate to form filtration slits which are approximately 25 nm 
wide along the capillary wall (Leaf and Cotran, 1976; and Ganong, 1999;). In the 
vessels, endothelial cells are sensitive to shear stress. When the shear stress exceeds 
a critical values, the cell begin to proliferate (Davies, 1989). This will lead to an 
increase iJ!. the diameter of the vessel and thus decreasing the shear stress 
(LaBarbera, 1990). 
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1.2.1.2. Proximal Convoluted Tubule 
The proximal convoluted tubule is about 1 S nun long and 55 lJ.Il1 in diameter. 
The walls of this tubule are made up of a single layer of cells that are interdigitated 
with one another and are united by apical tight junction. Between the bases of these 
cells, there are extensions of the extracellular space called lateral intracellular 
spaces. The luminal edges of the cells have a striated brush border due to the 
presence of innumerable microvilli. The convoluted portion of the proximal tubule 
(pars convoluta) drains into the straight portion (pars recta) and terminate at the 
thin segment of the beginning part of the loop of Henle. The cortical nephrons have 
short loop of Henle while the juxtamedullary nephrons have longer loops. In 
humans, only 15% of the nephrons have long loops. The total length of the thin 
segment of the loop varies between 2 - 14 mm. It ends with the thick segment of 
the ascending limb, with the length of about 12 nun. The thick ascending limb of 
the loop of Henle reaches the glomerulus of the nephron from which the tubule arise 
and passes close to its afferent arteriole. The walls of the afferent arterioles contain 
the renin-secreting juxtaglomerular cells. At this point, the tubular epithelium is 
modified histologically to form the macula densa. The juxtaglomerular cells, the 
macula densa and the lacis cells near by are collectively known as the 
juxtaglomerular apparatus (Ganong, 1999) 
1.2.1.3. Distal Convoluted Tubule 
This tubule is about 5 mm long, its epithelial cell is lower than that of 
proximal ~bule, and although there are few microvilli, there is no distinct brush 
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border. The distal tubules are joint together to fonn collecting ducts that are about 
20 mm long and pass through the renal cortex and medulla to empty into the pelvis 
of the kidney at the apexes of the medullary pyn.mids. The epithelial cells of the 
collecting ducts are predominantly the principal cells (P-cells) and small number of 
intercalated cells (!-cells). The P cells are involved in Na+ reabsorption and 
vasopressin stimulated water absorption, while I cells are concerned with acid 
secretion and HC03- transport. The total length of the nephrons include the 
collecting ducts ranging from 45 to 65 mm. Type I medullary interstitial cells 
contain lipid droplets and are associated with the prostaglandin PgE2 secretion 
(Ganong, 1999). 
1.2.2. Renal Circulation 
The kidneys are highly vascularized organs, which are supplied with a renal 
artery and the renal vein that enters and exits at the hilum respectively. The renal 
artery arises from the abdominal aorta and the venous tributaries unite to fonn the 
single wide renal vein, which drains into the inferior vena cava (Lumley et a!., 
1996). 
The afferent arterioles are short and straight branches of interlobular 
arteries. Each divides into multiple capillary branches to fonn a tuft of vessels in the 
glomerulus. The capillaries coalesce to fonn the efferent arteriole, which in tum 
break up into capillaries that supply the tubules (peritubular capillaries) before 
:, 
.· . 
draining into the interlobular veins .. ·· The arterial segments between glomeruli and 
tubules are thus technically a portal system and the glomerular capillaries are the 
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i ~, only capillaries in the body that drain into the arterioles. However, there is a little 
smooth muscle in the efferent arterioles (Ganong, 1999). 
The capillaries draining the tubule of the cortical nephron form a peritubular 
network, whereas the efferent arterioles from the juxtamedullary glomeruli drain not 
only into the peritubular network, but also into vessels that form hairpin loops (the 
vasa recta). These loops dip into the medullary pyramids along side the loops of 
Henle. The efferent arteriole from each glomerulus breaks up into the capillaries 
that supply a number of different nephrons (Ganong, 1999). 
Approximately 25% of cardiac output goes to the kidneys, and the blood is 
filtered to remove waste and to regulate extracellular electrolytes and intravascular 
volume. Blood flow through the kidney is approximately 1,200- 1,300 ml/min and 
is distributed into a large number of vascular channels arranged in parallel circuits, 
each supplied by a similar perfusion pressure. · The vascular resistance of each 
channel thus governs local blood flow which may therefore show disproportionate 
changes in various regions of the kidney, a so-called "redistribution of the renal 
blood flow" (Aukland, 1980). The microvessels in the kidneys have the ability to 
show autoregulatory activity, i.e., to contracts upon pressure rise and dilates upon 
pressure drop (Baez, 1968; and Johnson and Intaglietta, 1976) (Figure 1.2). The 
intrarenal blood flow distribution is very important for renal functions and hence 
alterations in regional renal blood flow distribution will alter renal function (Regan 
eta!., 1995) . 
. · 
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